Nucleic acids encoding norovirus VP1 fusion proteins and VLPs comprising the norovirus VP1 fusion proteins are provided. Methods for norovirus VP1 fusion protein and norovirus VLP production in plants are also described. The VP1 fusion protein comprises, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain.

Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.

The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.

Provided is a GII.4 norovirus virus-like particle or active fragment thereof, and use thereof, the virus-like particle comprising or being composed of an amino acid sequence shown as SEQ ID NO: 4. Further, provided is a composition or a kit comprising the GII.4 norovirus virus-like particle, and use thereof. The objective of covering multiple genotypes is achieved by using a single antigen of the invention, the process difficulty of the preparation for a pharmaceutical composition or a vaccine can be reduced, and the production cost is decreased. Also, provided is a norovirus immune composition or a kit comprising GII.2, GII.4, GII.6, and GII.17 norovirus virus-like particles or active fragments thereof, and use thereof. By the composition or the kit comprising the four types of antigens provied by the invention, each of antigens can generate a cross-immune effect on other genotypes, not only multiple prevailing genotypes of noroviruses can be covered, but also a synergy of immune effects on the same genotypes to which the four types of antigens target.

The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.

The instant disclosure relates to pseudovirus nanoparticles (PVNPs) and compositions comprising PVNPs. The disclosed PVNPs may be comprised of fusion proteins that form an icosahedral structure and a nanoparticle shell. The disclosed fusion proteins may comprise a modified norovirus (NoV) S domain protein; a hemagglutinin I (HA1) antigen of the influenza hemagglutinin I (HA1) of influenza vims; and a peptide linker connecting the C-terminus of the NoV S domain to the HA1 antigen. The modified NoV S domain proteins form the interior nanoparticle shell of said PVNP composition and display the 60 HA1 antigens on the surface of the nanoparticle shell. Methods of making and using the PVNPs and compositions containing PVNPs are also disclosed.

Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.

Nucleic acids encoding norovirus VP1 fusion proteins and VLPs comprising the norovirus VP1 fusion proteins are provided. Methods for norovirus VP1 fusion protein and norovirus VLP production in plants are also described. The VP1 fusion protein comprises, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain.

The present invention provides a peptide that can be used to induce protective immunity to a norovirus belonging to a genotype of GII. A peptide comprising a portion of an amino acid sequence of a P domain of a VP1 protein of a norovirus, in which the norovirus belongs to any of genotypes of genogroup II (GII) (except genotype 4).